Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

COVID-19 Vaccine, adjuvanted - Novavax

Next Previous
Drug Profile

COVID-19 Vaccine, adjuvanted - Novavax

Alternative Names: Coronavirus vaccine - Novavax; COVID-19 vaccine - Novavax; COVOVAX; Covovax; Nuvaxovid; Nuvaxovid XBB.1.5; NVX-CoV-2373; NVX-CoV2601; NVX-CoV2705; NVX‑CoV2373 vaccine; Omicron XBB.1.5 subvariant vaccine with Matrix-M adjuvant; Recombinant spike protein of SARS-CoV-2 virus vaccine; SARS-CoV-2 recombinant spike protein nanoparticle vaccine; SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine - Novavax; SARS-CoV-2 rS nanoparticle vaccine; TAK-019

Latest Information Update: 29 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novavax
  • Developer Novavax; Serum Institute of India; Takeda
  • Class Adjuvants; COVID-19 vaccines; Protein vaccines; Synthetic vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed COVID 2019 infections

Most Recent Events

  • 20 May 2025 Novavax anticipates commercial launch of 2025-2026 COVID-19 vaccine formula in the U.S. for COVID-2019 infections
  • 20 May 2025 US FDA approves for COVID-2019 infections (In adolescents, In adults, In the elderly, Prevention) in USA
  • 14 Oct 2024 Novavax initiates a phase III trial for COVID-2019 infection (Prevention) (IM) (NCT06409663)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top